Clinical Trial Update: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating adverse events and changes in disease activity when Livmoniplimab is combined with Budigalimab in adults with hepatocellular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Livmoniplimab
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING